Genetic cardiomyopathies and channelopathies (GCMs) account for an estimated 20% of all heart failure cases in the U.S., yet fewer than 2% of eligible patients are currently tested. This presentation will describe the REIMAGINE-HF Phase I Initiative, a nationwide, society-governed descriptive analysis developed under the Heart Failure Society of America (HFSA) in collaboration with Labcorp/Invitae. Using de-identified, aggregate-level data from over 248,000 patients tested across the U.S. from 2015–2025, we will review the rapid 35-fold expansion of cardio-genetic testing volume (CAGR 35%), a consistent patient-level diagnostic yield of approximately 22%, and the leading actionable genes identified (MYBPC3, TTN, MYH7, KCNQ1, TTR). The session will also highlight critical access and representation gaps including a 3.2-fold urban-to-rural testing disparity and underrepresentation of Black and Hispanic patients relative to their burden of disease, and outline how the REIMAGINE-HF dashboard infrastructure will inform Phase II implementation pilots aimed at equitable, guideline-concordant GCM screening.
This activity is intended for trainees, fellows, physicians, APPs, nurses, pharmacists and pharmacologists who care for patients with heart failure.
At the conclusion of this activity, learners will be better able to:
-
Describe the current landscape of cardio-genetic testing utilization in U.S. clinical practice, including the decade-long growth trajectory and compound annual growth rate (CAGR) observed from 2015–2025.
-
Identify the diagnostic yield of cardio-genetic testing at the patient level and recognize the leading actionable genes — including MYBPC3, TTN, MYH7, KCNQ1, and TTR — and their clinical implications for heart failure management.
-
Recognize the geographic and demographic disparities in cardio-genetic testing access, including the urban-to-rural testing gap and underrepresentation of Black and Hispanic patients relative to their heart failure disease burden.
Program Agenda
All sessions are listed in Eastern Standard Time.
Welcome and Introductions
Amin Yehya, MD, MS, HF-Cert
Phase 1: Background RE-Imagine HF
Melvin Echols, MD, MSCR, FHFSA and Mustafa Ahmed, MD
Phase 2: From Imagination to Implementation
Ana Morales, MS, CGC
Phase 3: Implementation to Real World Data
Anjali Owens, MD
Panel Discussion
End of Seminar